Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trialReinhard Dummer, Keith T. Flaherty, Dirk Schadendorf et al.|The Lancet Oncology|2017Cited by 491
Efficacy of Zenocutuzumab in <i>NRG1</i> Fusion–Positive CancerAlison M. Schram, Alexander Drilon, Sai‐Hong Ignatius Ou et al.|New England Journal of Medicine|2025Cited by 104
Results of NEMO: A phase III trial of binimetinib (BINI) vs dacarbazine (DTIC) in <i>NRAS</i>-mutant cutaneous melanoma.Reinhard Dummer, Keith T. Flaherty, Dirk Schadendorf et al.|Journal of Clinical Oncology|2016Cited by 30